All In Biotech

Drug Trial Radar · NCT01386554

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

Aug 2011

Primary completion

Nov 21, 2016

Study completion May 5, 2017

Sponsor

Lead sponsor
MallinckrodtIndustry
Sponsor type
Industry
First posted
Jul 1, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide nephrologists with additional clinical evidence regarding the efficacy and safety of Acthar in subjects with treatment-resistant idiopathic membranous nephropathy. Approximately sixty (60) subjects will be randomized in this double-blind, parallel-group, placebo-controlled, multicenter study comparing Acthar and Placebo administered 2 times per week for a 24-week treatment period followed by a 24-week observation period. The primary objective of this study is to assess the proportion of treatment-resistant subjects (defined as subjects who either have had no response or have suffered a relapse after achieving a partial response to their most recent standard treatment regimen) who have a complete or partial remission of proteinuria in nephrotic syndrome due to idiopathic membranous nephropathy after 24 weeks of treatment.

Conditions

  • Proteinuria
  • Idiopathic Membranous Nephropathy

Interventions

  • Repository Corticotropin InjectionDrug

    Acthar given SC for 6 months

  • PlaceboDrug

    Placebo contains the same inactive ingredients as that used for H.P. Acthar Gel without the API. Placebo given SC for 6 months (80 U two times a week).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Complete or Partial Remission in Proteinuria at 24 WeeksTime frame: At Visit 8 (Week 24)

Locations

28 sites in 5 countries. Site status is shown where the registry gives one.

  • Mallinckrodt Investigational Site

    Sacramento, California

  • Mallinckrodt Investigational Site

    Stanford, California

  • Mallinckrodt Investigational Site

    Jacksonville, Florida

  • Mallinckrodt Investigational Site

    Atlanta, Georgia

  • Mallinckrodt Investigational Site

    Rochester, Minnesota

  • Mallinckrodt Investigational Site

    Reno, Nevada

  • Mallinckrodt Investigational Site

    New York, New York

  • Mallinckrodt Investigational Site

    Chapel Hill, North Carolina

  • Mallinckrodt Investigational Site

    Durham, North Carolina

  • Mallinckrodt Investigational Site

    Bethlehem, Pennsylvania

  • Mallinckrodt Investigational Site

    Charleston, South Carolina

  • Mallinckrodt Investigational Site

    Chattanooga, Tennessee

  • Mallinckrodt Investigational Site

    Houston, Texas

  • Mallinckrodt Investigational Site

    Lubbock, Texas

  • Mallinckrodt Investigational Site

    Toronto, Ontario, Canada

  • Mallinckrodt Investigational Site

    Temuco, Chile

  • Mallinckrodt Investigational Site

    La Serena, Coquimbo Region, Chile

  • Mallinckrodt Investigational Site

    Monterrey, Nuevo León, Mexico

  • Mallinckrodt Investigational Site

    San Nicolás de los Garza, Nuevo León, Mexico

  • Mallinckrodt Investigational Site 307

    Adana, Turkey (Türkiye)

  • Mallinckrodt Investigational Site 305

    Ankara, Turkey (Türkiye)

  • Mallinckrodt Investigational Site 308

    Ankara, Turkey (Türkiye)

  • Mallinckrodt Investigational Site 302

    Antalya, Turkey (Türkiye)

  • Mallinckrodt Investigational Site 301

    Istanbul, Turkey (Türkiye)

  • Mallinckrodt Investigational Site 309

    Istanbul, Turkey (Türkiye)

  • Mallinckrodt Investigational Site 303

    Izmir, Turkey (Türkiye)

  • Mallinckrodt Investigational Site 310

    Kocaeli, Turkey (Türkiye)

  • Mallinckrodt Investigational Site 304

    Mersin, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.